secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001062993-26-000819
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed Q2 FY2026 net loss $2.03M; cash drops to $7.0M; warns of material impact from pending US legislation on BayMedica
--------------------------------------------------------------------------------

- Net loss of $2.03M for Q2 FY2026 (EPS -$0.51) vs net loss $2.58M in prior year; gross profit fell to $184K from $461K.
- Cash and equivalents $7.0M at Dec 31, 2025 vs $11.1M at June 30, 2025; expects runway into Q4 calendar 2026.
- BayMedica revenues $0.8M, down 26% YoY, due to pending US legislation H.R. 5371 that may prohibit certain cannabinoid sales after Nov 12, 2026.
- INM-901 Alzheimer's candidate advanced: oral formulation showed robust bioavailability in large animal PK study; no adverse neural effects.
- R&D expenses fell to $0.6M from $0.9M; expects substantial increase in H2 FY2026 for IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000106299326000819/0001062993-26-000819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000106299326000819/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-26-000819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer